Experience
Israel Bio-Engineering Project
Amgen Inc., Immunex Corp.
Successfully argued before the U.S. Court of Appeals for the Federal Circuit on behalf of Amgen and Immunex the appeal of a district court infringement action involving the important biologic drug Enbrel®. The Federal Circuit affirmed the district court’s grant of summary judgment regarding ownership of the patent in suit.
Israel Bio-Engineering Project v. Amgen Inc., Immunex Corp., 04-1153, 06-1218, Fed. Cir., Judge Klausner
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Senju Pharmaceuticals Co.
Bausch Health Companies
Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc.
Alzheon, Inc.
District court ruling maintains patent and regulatory protection of Otsuka’s Abilify®
Otsuka Pharmaceutical Co., Ltd.
Hartig Drug Co. Inc. v. Senju Pharmaceutical Co. Ltd.
Senju Pharmaceuticals Co. Ltd.
Mylan Pharmaceuticals Inc. v. Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Incorporated
Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co. Ltd.
Superior Graphite Co. v. TIMCAL S.A., Ltd.
TIMCAL S.A., Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.